Company: NIVFW
Filing Date: 2025-10-31
Form Type: 424B3
Source: 0001213900-25-104469
Chunk: 125

Company: NewGenIvf Group Ltd
Filing Date: 2025-10-31
Form: 424B3
Chunk 125
---
 of the Company                 |     |                    |   (524,643 | ) |     |     |    130,193 |   |
| Other comprehensive (loss) income                                                 |     |                    |            |   |     |     |            |   |
| Foreign currency translation adjustment                                           |     |                    |     32,529 |   |     |     |    (22,704 | ) |
| Total comprehensive (loss) income                                                 |     |                    |   (441,572 | ) |     |     |     85,714 |   |
| Less: Total comprehensive (loss) income attributable to non-controlling interests |     |                    |     56,908 |   |     |     |    (27,621 | ) |
| Total comprehensive (loss) income attributable to the shareholders of the Company |     |                    |   (498,480 | ) |     |     |    113,335 |   |
| Earnings per share – basic                                                        |     |                    |      (66.2 | ) |     |     |      176.2 |   |
| – diluted                                                                         |     |                    |      (31.9 | ) |     |     |      176.2 |   |
| Weighted average shares outstanding * – basic                                     |     |                    |      7,162 |   |     |     |        615 |   |
| - diluted                                                                         |     |                    |     14,866 |   |     |     |        615 |   |

<div align='center'>70</div>

Revenue

NewGenIvf’s revenue
for the six months ended June 30, 2025 was $2,019,628 and was $2,686,902 for the six months ended June 30, 2024.

NewGenIvf’s
revenue increased by approximately 5.8% from US$5,136,153 in 2023 to US$5,433,375 in 2024.

IVF treatment services

NewGenIvf’s IVF treatment
service revenue increased by approximately 35.1% from US$4,021,696 in 2023 to 5,433,375 in 2024. This increase was primarily the result
of our continued expansion of clinics in Thailand and clinic in Kyrgyzstan focusing on IVF services.

Surrogacy and ancillary caring services

NewGenIvf’s surrogacy
and